Pre-clinical study of protective potency of candidate recombinant live pertussis vaccine for intranasal administration

The aim of present research is studying of protective potency of candidate recombinant live pertussis vaccine (RLPV) for intranasal administration.Materials and methods. Two methods of protective potency assessment, based on mice survival estimating, were used: after intracerebral administration of B.pertussis 18323 bacteria and after intranasal administration of virulent Bordetella spp. bacteria (B.pertussis, B.parapertussis and B.bronchiseptica) to immunized mice.Results. An ingenious method of pertussis vaccine protective potency assessment due to mucosal immunity is suggested. Protective potency of constructed RLPV estimated in two tests of intracerebral and intranasal administration was higher than market image drug of DTP vaccine. RLPV provided protection from infection in mice after administration of both wild type and recombinant Bordetella spp. bacteria.Conclusion. Examined recombinant live pertussis vaccine (RLPV) for intranasal administration has significant protective potential and could be recommended for using in clinical trials